vadastuximab talirine + cytarabine + daunorubicin

This is a combination therapy consisting of **vadastuximab talirine**, **cytarabine**, and **daunorubicin**. - **Vadastuximab talirine** is an antibody-drug conjugate (ADC) targeting CD33. The humanized monoclonal antibody is conjugated to the synthetic DNA–crosslinking pyrrolobenzodiazepine (PBD) dimer SGD-1882 via a cleavable linker. Upon binding to CD33, which is highly expressed on acute myeloid leukemia (AML) cells, the ADC is internalized, and the cytotoxic payload is released, causing DNA crosslinking and apoptosis in CD33-positive cells[1][2][4][6]. - **Cytarabine** is a cytidine nucleoside analog that inhibits DNA synthesis, primarily by incorporation into DNA and inhibition of DNA polymerase. - **Daunorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and preventing DNA replication. The main context for this combination is as an investigational regimen for the treatment of **acute myeloid leukemia (AML)**. Most published work has focused on vadastuximab talirine as monotherapy or in combination with hypomethylating agents, but it has also been considered for use with intensive chemotherapy regimens such as cytarabine and daunorubicin[1][4][5][6]. Developers for vadastuximab talirine include **Seagen** (formerly Seattle Genetics)[2][6]. Cytarabine and daunorubicin are long-established chemotherapies with multiple generic manufacturers.

Other names

SGN-CD33A + cytarabine + daunorubicin